STER-BAC

Informasi Utama

  • Nama dagang:
  • STER-BAC
  • Digunakan untuk:
  • manusia
  • Jenis Obat:
  • Perangkat medis

Dokumen

  • untuk masyarakat umum:
  • Informasi leaflet untuk produk ini saat ini tidak tersedia, Anda dapat mengirim permintaan untuk layanan pelanggan kami dan kami akan memberitahu Anda segera setelah kami mampu mendapatkannya.


    Meminta selebaran informasi untuk masyarakat umum.

Lokalisasi

  • Tersedia di:
  • STER-BAC
    Indonesia
  • Bahasa:
  • Bahasa Indonesia

Informasi lainnya

Status

  • Sumber:
  • Ecolab
  • Nomor Otorisasi:
  • 900316-02
  • Pembaharuan Terakhir:
  • 12-03-2018

Ringkasan karakteristik Produk: dosis, interaksi, efek samping

STER-BAC

Pendesinfeksi.

LEMBAR DATA KEAMANAN

Nama produk

Penggunaan dan

pembatasan yang

direkomendasikan

Nomor telepon darurat

:

:

Informasi pemasok

:

STER-BAC

Gunakan hanya untuk tujuan pada label produk.

:

Bagian 1. Identifikasi produk kimia dan perusahaan

Nama-nama lain

:

Tidak ada.

Informasi pengenceran

produk

:

0.0 - 0.2%

PT. Ecolab Indonesia

Jl. Jababeka XII Kav V-37

Kawasan Industri jababeka, Cikarang

Indonesia 17350

Tel : (62-21) 5707557 Fax : (62-21) 5707682

+1 651-222-5352

TOKSISITAS AKUT: ORAL - 5

KOROSI/IRITASI KULIT - 1B

IRITASI/ KERUSAKAN PARAH PADA MATA -

BAHAYA TOKSISITAS AKUT PADA

LINGKUNGAN AKUATIK - 2

Klasifikasi GHS

(Globally

Harmonised System

~ Sistim Harmonisasi

Global)

:

Kata sinyal

:

Berbahaya

Pernyataan bahaya

:

Mungkin berbahaya bila tertelan.

Menyebabkan luka bakar yang parah pada kulit

dan kerusakan mata.

Beracun terhadap kehidupan akutik.

Piktogram

:

Pernyataan kehati-hatian

Pencegahan

:

Kenakan sarung tangan pelindung. Kenakan

pelindung mata atau wajah. Kenakan pakaian

pelindung. Hindari pelepasan ke lingkungan.

Cuci tangan dengan bersih setelah

penanganan.

2. Identifikasi Bahaya

Elemen label GHS

Produk TERJUAL

Penggunaan produk dicairkan

Tidak diklasifikasikan.

Tanpa Kata Sinyal

Tidak diketahui efek signifikan atau bahaya

kritis.

Cuci sepenuhnya sesudah penanganan.

900316-02

Halaman: 1/8

STER-BAC

2. Identifikasi Bahaya

Tanggapan

:

JIKA TERHIRUP: Pindahkan korban ke udara

segar dan menjaga nyaman untuk bernafas.

Segera hubungi Pusat Penanggulangan

Keracunan atau tenaga medis. JIKA

TERTELAN: Segera hubungi Pusat

Penanggulangan Keracunan atau tenaga

medis. Kumur. JANGAN merangsang muntah.

JIKA TERKENA KULIT (atau rambut): Segera

tanggalkan semua pakaian yang

terkontaminasi. Cuci kult dengan air atau

pancuran. Cuci pakaian yang terkontaminasi

sebelum dipakai kembali. Segera hubungi

Pusat Penanggulangan Keracunan atau tenaga

medis. JIKA TERKENA MATA: Bilas secara

hati-hati dengan air selama beberapa menit.

Lepaskan lensa kontak jika memakainya dan

mudah dilakukan. Lanjutkan membilas. Segera

hubungi Pusat Penanggulangan Keracunan

atau tenaga medis.

Penyimpanan

:

Tidak teridentifikasi adanya tindakan khusus

lainnya.

Pembuangan

:

Buang isi dan wadah sesuai dengan peraturan

lokal, regional, nasional dan internasional.

Bahaya lain

:

Tidak diketahui.

Tidak berlaku.

Tidak teridentifikasi adanya tindakan khusus

lainnya.

Tidak berlaku.

Tidak diketahui.

Campuran

3. Komposisi/ Informasi tentang Bahan Penyusun Senyawa tunggal

Zat/sediaan

:

BENZIL-(C12-C16 ALKIL)-DIMETIL-AMONIUM KLORIDA

10 - 30

68424-85-1

ETIL ALKOHOL

1 - 10

64-17-5

Komponen-komponen yang berbahaya

Nomor CAS

Rentang konsentrasi (%)

Produk TERJUAL

Penggunaan produk dicairkan

Tidak terdapat bahan yang, sejauh pengetahuan pemasok saat ini dan pada konsentrasi yang berlaku,

diklasifikasikan sebagai berbahaya pada kesehatan atau lingkungan dan karenanya diperlukan pelaporan dalam

bagian ini.

Bilas secara hati-hati dengan air selama

beberapa menit. Lepaskan lensa kontak jika

memakainya dan mudah dilakukan. Lanjutkan

membilas. Segera dapatkan pertolongan medis.

Segera tanggalkan semua pakaian yang

terkontaminasi. Cuci kult dengan air atau

pancuran. Segera dapatkan pertolongan medis.

Cuci pakaian sebelum dikenakan lagi. Bersihkan

sepatu secara menyeluruh sebelum digunakan

kembali.

Pindahkan korban ke udara segar dan

istirahatkan pada posisi yang nyaman untuk

bernafas. Segera dapatkan pertolongan medis.

Kontak mata

Kontak kulit

Penghirupan

:

:

:

4. Tindakan Pertolongan Pertama

Produk TERJUAL

Penggunaan produk dicairkan

Efek setelah terkena mata tidak diketahui.

Bilas dengan air selama beberapa menit.

Efek setelah terkena kulit tidak diketahui.

Bilas dengan air selama beberapa menit.

Tidak perlu tindakan khusus. Obati

berdasarkan gejala.

900316-02

Halaman: 2/8

STER-BAC

4. Tindakan Pertolongan Pertama

Segera dapatkan pertolongan medis. Kumur.

Jangan memaksa muntah.

Tertelan

:

Perlindungan bagi

penolong pertama

:

Tidak boleh melakukan tindakan yang menyangkut risiko pribadi atau tanpa pelatihan yang

sesuai. Mungkin dapat membahayakan bagi orang yang memberikan pertolongan resusitasi dari

mulut-ke-mulut. Cuci pakaian yang terkontaminasi dengan air sampai bersih sebelum

melepaskannya, atau memakai sarung tangan.

Catatan untuk

dokter

:

Obati berdasarkan gejala. Segera menghubungi ahli perawatan racun jika jumlah besar

termakan atau terhirup.

Lihat informasi toksikologi (bagian 11)

Dapatkan pertolongan medis jika terjadi

gejala.

Jika ada kebakaran segera isolasi tempat kejadian dengan menjauhkan semua

orang dari lokasi kebakaran. Tidak boleh melakukan tindakan yang menyangkut

risiko pribadi atau tanpa pelatihan yang sesuai.

Produk dekomposisi termal

berbahaya

Bahaya spesifik yang

diakibatkan bahan kimia

tersebut

Bahan-bahan berikut ini mungkin dapat termasuk golongan produk penguraian-

hayati:

karbon dioksida

karbon monoksida

Dalam kebakaran atau jika dipanaskan, peningkatan tekanan akan terjadi dan

wadah bisa meledak. Bahan ini toksik bagi kehidupan air. Air bekas memadamkan

kebakaran yang tercemar dengan bahan ini harus dibendung dan dicegah agar

tidak mengalir masuk/dibuang ke saluran air, parit, atau selokan.

Petugas pemadam kebakaran harus memakai perlengkapan pelindung yang

memadai dan alat bantu pernapasan (Self-Contained Breathing Apparatus - SCBA)

yang berpelindung-wajah penuh dan yang beroperasi dalam mode tekanan positif.

Alat pelindung khusus

untuk petugas pemadam

kebakaran

Gunakan semprotan air, kabut atau busa.

:

:

:

Media yang sesuai untuk

pemadaman kebakaran

:

:

5. Tindakan Pemadaman Kebakaran

Produk TERJUAL

Langkah-langkah

pencegahan bagi

lingkungan

Tindakan

pencegahan pribadi

:

:

Segera laksanakan prosedur perusahaan untuk

menanggulangi tumpahan. Jauhkan orang-orang

dari tepat tumpahan. Kenakan perlengkapan

pelindung pribadi yang layak (lihat bagian 8).

Jangan menyentuh atau berjalan kaki melintasi

tumpahan bahan.

Mencegah pengaliran tumpahan bahan ke tanah

dan ke saluran air yang terbuka.

Patuhi prosedur perusahaan mengenai

tumpahan. Jauhkan orang-orang dari tumpahan.

Kenakan perlengkapan pelindung pribadi yang

layak (lihat bagian 8). Serap/netralisasi bahan

cairan. Gunakan alat untuk menyekop padatan

atau bahan yang terserap dan masukkan ke

dalam wadah berlabel yang layak. Gunakan alat

untuk menyekop padatan atau bahan yang

terserap lalu masukkan ke dalam wadah limbah

berlabel yang layak. Gunakan air bilas untuk

pembersihan akhir.

Metode untuk

membersihan

:

6. Tindakan Penanggulangan jika terjadi Kebocoran

Produk TERJUAL

Penggunaan produk dicairkan

Gunakan alat pelindung diri sesuai

kebutuhan.

Jaga agar tumpahan bahan dalam jumlah

banyak tidak mengalir ke tanah dan saluran

air di permukaan tanah.

Gunakan air bilas untuk pembersihan akhir.

900316-02

Halaman: 3/8

STER-BAC

Menangani/

Penanganan

Penyimpanan

Jangan dimakan/diminum. Jangan terkena mata

atau kulit atau pakaian. Jangan menghirup uap

atau kabut. Gunakan hanya dengan ventilasi

yang memadai. Cuci sepenuhnya sesudah

penanganan.

Jauhkan dari jangkauan anak-anak. Pastikan

wadah tertutup rapat.

:

:

7. Penanganan dan Penyimpanan

Produk TERJUAL

Penggunaan produk dicairkan

Cuci sepenuhnya sesudah penanganan.

Jauhkan dari jangkauan anak-anak.

Simpan dalam suhu antara: -10 dan 50°C

Perlindungan

tangan

Tidak diperlukan respirator dalam kondisi normal

dan kondisi yang ditentukan untuk penggunaan

produk.

Gunakan sarung tangan yang kuat, tahan-kimia.

Gunakan kacamata pelindung. Selanjutnya

gunakan pelindung wajah.

Perlindungam mata

Perlindungan

pernapasan

:

:

:

Perlindungan kulit

Gunakan celemek sintetis, peralatan pelindung

lainnya yang diperlukan untuk mencegah kontak

kulit.

:

Pengendalian teknik

yang sesuai

:

Gunakan hanya dengan ventilasi yang memadai.

Jika pengoperasian pemakai menimbulkan debu,

asap, gas, uap atau kabut, gunakan daerah kerja

terkurung, ventilasi pembuangan lokal atau

kontrol teknis lainnya untuk menjaga agar

pekerja tidak terbuka terhadap kontaminan

terbawa-udara di atas batas yang

direkomendasikan atau ketentuan hukum.

Menyediakan fasilitas untuk cepat membasahi

atau pembilasan pada mata dan tubuh pada

kasus kontak atau bahaya lain.

Cuci tangan, lengan dan wajah sampai bersih setelah menangani produk kimia, sebelum

makan, merokok dan menggunakan WC dan seusai waktu kerja. Teknik yang sesuai harus

digunakan untuk melepaskan/membuang pakaian berpotensi terkontaminasi. Cuci pakaian

yang terkontaminasi sebelum dipakai kembali.

Tindakan higienis

:

Parameter pengendalian

Perlindungan perorangan

8. Kontrol Paparan/Perlindungan Diri

Produk TERJUAL

Penggunaan produk dicairkan

Ventilasi umum yang baik semestinya cukup

untuk mengendalikan pemaparan pekerja

terhadap kadar kontaminasi yang terbawa-

udara.

Tidak ada peralatan pelindung yang

dibutuhkan dalam kondisi pemakaian normal.

Tidak ada peralatan pelindung yang

dibutuhkan dalam kondisi pemakaian normal.

Tidak diperlukan respirator dalam kondisi

normal dan kondisi yang ditentukan untuk

penggunaan produk.

ETIL ALKOHOL

Departemen Tenaga Kerja (Indonesia,

2/2005).

NAB: 1880 mg/m³ 8 jam.

NAB: 1000 BDS 8 jam.

Nama bahan

Batas pemaparan

Tidak ada peralatan pelindung yang

dibutuhkan dalam kondisi pemakaian normal.

900316-02

Halaman: 4/8

STER-BAC

Bentuk fisik

Titik lebur

Tekanan uap

Kerapatan relatif

Rapat uap

Kelarutan

Cairan.

Tidak tersedia.

0.995 (Air = 1)

Tidak tersedia.

Tidak tersedia.

Dengan mudah dapat larut pada bahan-bahan

berikut: air dingin dan air panas.

Rasa manis

Bau

pH

Bening hingga kuning muda.

Warna

Laju penguapan

(butil asetat = 1)

Tidak tersedia.

Suhu dapat

membakar sendiri

(auto-ignition)

Titik nyala

Tidak tersedia.

> 100°C

Produk tidak mendukung pembakaran

Tidak tersedia.

7.5 (100%)

Kekentalan

Tidak tersedia.

Koefisien partisi (n-

oktanol/air)

:

:

:

:

:

:

:

:

:

:

:

:

:

:

Titik didih

:

>100°C (>212°F)

Flamabilitas

(padatan, gas)

:

Tidak tersedia.

Batas ledakan

:

Tidak tersedia.

9. Sifat Fisika dan Kimia

Produk TERJUAL

Penggunaan produk dicairkan

Cairan.

Tidak berwarna

Tidak berbau

7.5 sampai dengan 7.5

> 100°C

Suhu penguraian

Ambang bau

:

:

Tidak tersedia.

Tidak tersedia.

Hasil peruraian yang

berbahaya

Kondisi untuk dihindarkan

Tidak ada data khusus.

Pada kondisi penyimpanan dan penggunaan yang normal, produk-produk

penguraian-hayati yang berbahaya seharusnya tidak terproduksi.

Produk ini stabil.

Stabilitas

Tidak tersedia.

:

:

:

Bahan untuk dihindari

:

Kemungkinan reaksi yang

berbahaya

:

Dibawah kondisi penyimpanan dan penggunaan yang normal, reaksi yang

berbahaya tidak akan terjadi.

10. Stabilitas dan Reaktifitas

Produk TERJUAL

Rute Paparan

:

Kontak kulit, Kontak mata, Penghirupan, Tertelan

11. Informasi Toksikologi

Gejala

Kontak mata

:

Gejala-gejala gangguan kesehatan mungkin

akan meliputi:

sakit/nyeri

berair

kemerahan

Produk TERJUAL

Penggunaan produk dicairkan

Tidak ada data khusus.

900316-02

Halaman: 5/8

STER-BAC

11. Informasi Toksikologi

Data toksisitas

Nama produk/bahan

Hasil

Spesies

Dosis

Tidak diketahui efek signifikan atau bahaya kritis.

Karsinogenisitas

:

Tidak diketahui efek signifikan atau bahaya kritis.

Mutagenisitas

:

Tidak diketahui efek signifikan atau bahaya kritis.

Teratogenisitas

:

Efek-efek perkembangan

selama masa pertumbuhan

:

Tidak diketahui efek signifikan atau bahaya kritis.

Efek-efek kesuburan

:

Tidak diketahui efek signifikan atau bahaya kritis.

Toksisitas kronis

Toksisitas akut

Penghirupan

:

Dapat menyebabkan iritasi pernafasan.

Mungkin berbahaya bila tertelan. Dapat

menyebabkan luka bakar pada mulut,

tenggorokan dan perut.

:

Tertelan

Kontak kulit

:

Menyebabkan luka bakar parah.

Menyebabkan kerusakan serius pada mata.

:

Kontak mata

Kontak kulit

Tertelan

Penghirupan

Gejala-gejala gangguan kesehatan mungkin

akan meliputi:

batuk

Iritasi saluran pernapasan

Gejala-gejala gangguan kesehatan mungkin

akan meliputi:

sakit perut

Gejala-gejala gangguan kesehatan mungkin

akan meliputi:

pedih atau iritasi

kemerahan

kelepuhan bisa terjadi

:

:

:

Tidak ada data khusus.

Tidak ada data khusus.

Tidak ada data khusus.

Tidak diketahui efek signifikan atau bahaya

kritis.

Tidak diketahui efek signifikan atau bahaya

kritis.

Tidak diketahui efek signifikan atau bahaya

kritis.

Tidak diketahui efek signifikan atau bahaya

kritis.

BENZIL-(C12-C16 ALKIL)-DIMETIL-

AMONIUM KLORIDA

LD50 Dermal

Kelinci

3340 mg/kg

LD50 Oral

Tikus besar

344 mg/kg

ETIL ALKOHOL

LC50 Penghirupan Uap

Tikus besar

117 mg/l

LD50 Dermal

Kelinci

15800 mg/kg

LD50 Oral

Tikus besar

10470 mg/kg

LogP

ow

BCF

Potensial

Potensi bioakumulasi

Nama produk/bahan

Efek keracunan pada organisme air dan darat

Nama produk/bahan

Spesies

Hasil

Pemaparan

Persistensi dan kemudahan terurai

Nama produk/bahan

Uji

Dosis

Hasil

Zat inokulasi

Ekotoksisitas

:

Bahan ini toksik bagi kehidupan air.

12. Informasi Ekologi

Produk TERJUAL

BENZIL-(C12-C16 ALKIL)-DIMETIL-AMONIUM

KLORIDA

Akut LC50 0.515 mg/l

Ikan

96 jam

ETIL ALKOHOL

Akut LC50 11000 mg/l

Ikan

96 jam

Tidak tersedia.

ETIL ALKOHOL

-0.31

rendah

900316-02

Halaman: 6/8

STER-BAC

12. Informasi Ekologi

Mobilitas dalam tanah

Tidak tersedia.

:

Efek merugikan lainnya

:

Tidak diketahui efek signifikan atau bahaya kritis.

Hindari pembuangan. Upayakan untuk

menggunakan produk seluruhnya sesuai dengan

maksud penggunaannya. Pembuangan harus

sesuai dengan hukum dan peraturan yang

berlaku di tingkat regional, nasional dan lokal.

:

Metode

pembuangan

13. Pertimbangan Pembuangan/Pemusnahan

Produk TERJUAL

Penggunaan produk dicairkan

Produk diencerkan dapat disalurkan ke

saluran pembuangan sanitasi Buang

kemasan kosong di tempat sampah

Nomor PBB Nama pengapalan yang sesuai

Penggolongan

Informasi

pengaturan

PG*

Informasi tambahan

PG* : Kelompok pengemasan

Lihat dokumen pengapalan untuk informasi transportasi tertentu.

14. Informasi Transportasi

Produk TERJUAL

Penggunaan produk dicairkan

Tidak dimaksudkan untuk

transportasi.

Kelas ADR/RID

UN3082

ENVIRONMENTALLY

HAZARDOUS SUBSTANCE,

LIQUID, N.O.S. (BENZIL-

(C12-C16 ALKIL)-DIMETIL-

AMONIUM KLORIDA) Polutan

bahari

Nomor identifikasi

bahaya

Jumlah yang terbatas

Ketentuan khusus

274, 335, 601

Kode terowongan

Kelas IMDG

UN3082

ENVIRONMENTALLY

HAZARDOUS SUBSTANCE,

LIQUID, N.O.S. (BENZIL-

(C12-C16 ALKIL)-DIMETIL-

AMONIUM KLORIDA). Polutan

bahari

Jadwal darurat (EmS)

F-A, S-F

15. Informasi yang berkaitan dengan Regulasi

Regulasi tentang

lingkungan, kesehatan

dan keamanan untuk

produk tersebut

:

Produk TERJUAL

Penggunaan produk dicairkan

Sejauh diketahui tidak ada peraturan nasional

atau kedaerahan spesifik yang berlaku untuk

produk ini (termasuk bahan-bahan produk

tersebut).

Sejauh diketahui tidak ada peraturan

nasional atau kedaerahan spesifik yang

berlaku untuk produk ini (termasuk bahan-

bahan produk tersebut).

900316-02

Halaman: 7/8

STER-BAC

Sejarah / Riwayat

Tanggal terbitan

Informasi di atas diyakini benar sehubungan dengan formula yang digunakan untuk memproduksi produk di

negara asal. Sebagai data, standar, dan perubahan peraturan, dan ketentuan penggunaan dan penanganan

berada di luar kendali kami, TIDAK ADA GARANSI, TERSURAT MAUPUN TERSIRAT, DIBUAT SEBAGAI

KELENGKAPAN ATAU AKURASI LANJUTAN DARI INFORMASI INI.

Pemberitahuan kepada pembaca

Tanggal terbitan

sebelumnya

:

:

16. Informasi Lain

Referensi

Disiapkan oleh

:

Urusan peraturan

Tidak tersedia.

25 Mar 2013

30 Okt 2012

900316-02

Halaman: 8/8

18-2-2019

Meer BIG-registraties verpleegkundigen, fysiotherapeuten en verloskundigen

Meer BIG-registraties verpleegkundigen, fysiotherapeuten en verloskundigen

Het aantal zorgverleners met een BIG-registratie in de beroepen verpleging, fysiotherapie en verloskunde is de afgelopen jaren gestaag gestegen. Dat meldt minister Bruno Bruins voor Medische Zorg en Sport in een brief aan de Tweede Kamer. In de periode 2014-2018 waren er in deze beroepen bijna 47.000 nieuwe registraties in het BIG-register. Daar stonden 33.350 doorhalingen tegenover van zorgverleners die niet opnieuw geregistreerd konden of wilden worden. De netto stijging komt daarmee op 13.650 geregist...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

11-2-2019


Online training: How to register for access to IRIS, European Medicines Agency, London, UK, from 31/01/2019 to 31/01/2019

Online training: How to register for access to IRIS, European Medicines Agency, London, UK, from 31/01/2019 to 31/01/2019

Online training: How to register for access to IRIS, European Medicines Agency, London, UK, from 31/01/2019 to 31/01/2019

Europe - EMA - European Medicines Agency

25-1-2019

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 9: suitability of taxonomic units notified to EFSA until September 2018

Update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA 9: suitability of taxonomic units notified to EFSA until September 2018

Published on: Thu, 24 Jan 2019 The qualified presumption of safety (QPS) procedure was developed to provide a harmonised generic pre‐evaluation to support safety risk assessments of biological agents performed by EFSA's Scientific Panels. The taxonomic identity, body of knowledge, safety concerns and antimicrobial resistance were assessed. Safety concerns identified for a taxonomic unit are, where possible and reasonable in number, reflected by ‘qualifications’ which should be assessed at the strain lev...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

SIGMA Animal Disease Data Model: A comprehensive approach for the collection of standardised data on animal diseases

SIGMA Animal Disease Data Model: A comprehensive approach for the collection of standardised data on animal diseases

Published on: Mon, 21 Jan 2019 The European Commission is routinely asking EFSA for scientific and technical support in the epidemiological analysis of animal disease outbreaks (i.e. African swine fever, lumpy skin disease and avian influenza) and to report or assess surveillance data (i.e. Echinococcus multilocularis and avian influenza). For this purpose, EFSA has over the last years carried out several data collections and gathered specific information on outbreaks, surveillance activities and concer...

Europe - EFSA - European Food Safety Authority EFSA Journal

22-1-2019

Peer review of the pesticide risk assessment of the active substance fenamiphos

Peer review of the pesticide risk assessment of the active substance fenamiphos

Published on: Mon, 21 Jan 2019 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authorities of the rapporteur Member State Greece and co‐rapporteur Member State Cyprus for the pesticide active substance fenamiphos are reported. The context of the peer review was that required by Commission Implementing Regulation (EU) No 844/2012. The conclusions were reached on the basis of the evaluation of the representative uses of fenamiphos as a nematic...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Safety and efficacy of Lactobacillus reuteri NBF‐2 (DSM 32264) as a feed additive for cats

Safety and efficacy of Lactobacillus reuteri NBF‐2 (DSM 32264) as a feed additive for cats

Published on: Fri, 11 Jan 2019 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Lactobacillus reuteri NBF‐2 when used in feed for cats at a minimum dose of 6 × 109 colony forming units (CFU) per animal and day. The additive is a preparation of viable cells of L. reuteri DSM 32264. This species is considered by EFSA to be suitable for the qualified presum...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-1-2019

Safety and efficacy of Lactobacillus reuteri NBF‐1 (DSM 32203) as a feed additive for dogs

Safety and efficacy of Lactobacillus reuteri NBF‐1 (DSM 32203) as a feed additive for dogs

Published on: Fri, 11 Jan 2019 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of Lactobacillus reuteri NBF‐1 when used in feed for dogs at a minimum dose of 6 × 109 colony forming units (CFU) per animal and day. The additive is a preparation of viable cells of L. reuteri DSM 32203. This species is considered by the European Food Safety Authority to be sui...

Europe - EFSA - European Food Safety Authority EFSA Journal

20-12-2018

Workshop on Avian Influenza

Workshop on Avian Influenza

Published on: Wed, 19 Dec 2018 Since September 2017, EFSA has been providing ongoing scientific and technical support to the European Commission and Member States (MSs) in the collection, collation, and analysis of epidemiological data relevant to the monitoring of avian influenza (AI) viruses in Europe and third countries. From 2019 onwards, EFSA will also be responsible for collecting, collating, and analysing the data gathered by MSs via their surveillance programmes in poultry and wild birds. To eff...

Europe - EFSA - European Food Safety Authority EFSA Journal

1-12-2018

Safety assessment of the process ‘RecyPET Hungária’, based on RecyPET Hungária technology, used to recycle post‐consumer PET into food contact materials

Safety assessment of the process ‘RecyPET Hungária’, based on RecyPET Hungária technology, used to recycle post‐consumer PET into food contact materials

Published on: Fri, 30 Nov 2018 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP) assessed the safety of the recycling process RecyPET Hungária (EU register number RECYC0146). The input is hot caustic washed and dried poly(ethylene terephthalate) (PET) flakes originating from collected post‐consumer PET containers, containing no more than 5% of PET from non‐food applications. The flakes are dried and extruded. The output of the extrusion step is cut into pellets in an underwater...

Europe - EFSA - European Food Safety Authority Publications

30-11-2018

Reporting Avian Influenza surveillance

Reporting Avian Influenza surveillance

Published on: Thu, 29 Nov 2018 Avian influenza viruses infect domestic poultry and wild birds as well as humans. In poultry, depending on whether these viruses are of high pathogenicity (HPAI) or low pathogenicity (LPAI), the infection can cause different clinical signs, with HPAI causing high mortality in poultry flocks. In order to ensure early detection of avian influenza viruses, surveillance in poultry and wild birds is considered essential. In 2010, the European Commission provided some guidelines...

Europe - EFSA - European Food Safety Authority Publications

24-11-2018

Blokhuis: 1,25 miljoen euro voor educatie Tweede Wereldoorlog

Blokhuis: 1,25 miljoen euro voor educatie Tweede Wereldoorlog

Staatssecretaris Paul Blokhuis van Volksgezondheid, Welzijn en Sport heeft 1,25 miljoen euro beschikbaar gesteld voor educatieprojecten over de Tweede Wereldoorlog. In 2019 en 2020 vieren we dat Nederland 75 jaar is bevrijd, eerst het zuidelijke deel in 1944 en daarna de rest van Nederland en Nederlands-Indië in 1945. Dit lustrumjaar wordt de bevrijding nog groter gevierd dan anders en wordt er extra nadruk gelegd op het herinneren van de oorlog. De 1,25 miljoen euro komt boven op de 3,5 miljoen voor ond...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

10-11-2018

Pest categorisation of Popillia japonica

Pest categorisation of Popillia japonica

Published on: Thu, 08 Nov 2018 00:00:00 +0100 The Panel on Plant Health performed a pest categorisation of Popillia japonica(Coleoptera: Scarabaeidae) for the EU. P. japonica is a distinguishable species listed in Annex IAII of Council Directive 2000/29/EC. It is native to Japan but established in the USA in the early 20th century. It spreads from New Jersey to most US states east of the Mississippi, some to the west and north into Canada. P. japonica feeds on over 700 plant species. Adults attack folia...

Europe - EFSA - European Food Safety Authority Publications

7-11-2018

Kadesh Incorporation Issues Voluntary Nationwide Recall of Puriton Eye Relief Drops Due to Non-Sterile Production Conditions

Kadesh Incorporation Issues Voluntary Nationwide Recall of Puriton Eye Relief Drops Due to Non-Sterile Production Conditions

Kadesh, Inc. of Garden Grove, CA is voluntarily recalling all lots of Puriton Eye Relief Drops, 0.5 oz. (15ml) bottle, UPC 7 36972 1679 0, to the consumer level. During a recent FDA inspection, investigators observed that ophthalmic drugs, which are required to be sterile, are manufactured without necessary production controls and conditions to assure sterility.

FDA - U.S. Food and Drug Administration

31-10-2018

Safety and efficacy of Lactobacillus hilgardii CNCM I‐4785 and Lactobacillus buchneri CNCM I‐4323/NCIMB 40788 as a silage additive for all animal species

Safety and efficacy of Lactobacillus hilgardii CNCM I‐4785 and Lactobacillus buchneri CNCM I‐4323/NCIMB 40788 as a silage additive for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed was asked to deliver a scientific opinion on the safety and efficacy of a strain of Lactobacillus hilgardii and of Lactobacillus buchneri when used as a technological additive intended to improve ensiling at a proposed application rate of 3.0 x 108 colony forming units (CFU)/kg fresh material. The two bacterial species are considered by EFS...

Europe - EFSA - European Food Safety Authority Publications

2-10-2018

October 1, 2018: AmerisourceBergen Corp. to Pay $625 Million to Settle Civil Fraud Allegations Resulting from Its Repackaging and Sale of Adulterated Drugs and Unapproved New Drugs, Double Billing and Providing Kickbacks

October 1, 2018: AmerisourceBergen Corp. to Pay $625 Million to Settle Civil Fraud Allegations Resulting from Its Repackaging and Sale of Adulterated Drugs and Unapproved New Drugs, Double Billing and Providing Kickbacks

October 1, 2018: AmerisourceBergen Corp. to Pay $625 Million to Settle Civil Fraud Allegations Resulting from Its Repackaging and Sale of Adulterated Drugs and Unapproved New Drugs, Double Billing and Providing Kickbacks

FDA - U.S. Food and Drug Administration

27-9-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on modernizing standards of identity and the use of dairy names for plant-based substitutes

Statement from FDA Commissioner Scott Gottlieb, M.D., on modernizing standards of identity and the use of dairy names for plant-based substitutes

FDA issues a request for information to solicit feedback on how consumers are using plant-based substitutes for milk, cheese and other dairy foods.

FDA - U.S. Food and Drug Administration

25-9-2018

FDA Announces FY 2019 Animal Drug User Fee Rates for ADUFA and AGDUFA

FDA Announces FY 2019 Animal Drug User Fee Rates for ADUFA and AGDUFA

The U.S. Food and Drug Administration announced in the Federal Register today the fiscal year 2019 rates and payment procedures for animal drugs subject to user fees under the Animal Drug User Fee Amendments of 2018 (ADUFA IV) and Animal Generic Drug User Fee Amendments of 2018 (AGDUFA III).

FDA - U.S. Food and Drug Administration

29-8-2018

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Published on: Tue, 21 Aug 2018 00:00:00 +0200 Abstract In May 2018, EFSA and ECDC co‐facilitated a workshop on preparedness for a multi‐national food safety/public health incident. The workshop, hosted at AGES in Vienna, was conceived to closely align with EFSA's Strategy 2020 commitment to prepare for future risk assessment challenges. EFSA, ECDC, AGES and BfR worked together closely to develop a workshop and associated training materials to be delivered over a 2.5‐day agenda. The workshop was attended...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Safety assessment of the process ‘General Plastic’, based on Starlinger Decon technology, used to recycle post‐consumer PET into food contact materials

Published on: Fri, 10 Aug 2018 00:00:00 +0200 This scientific opinion of the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) deals with the safety evaluation of the recycling process General Plastic (EU register No RECYC153), which is based on the Starlinger Decon technology. The decontamination efficiency of the process was demonstrated by a challenge test. The input of this process is hot caustic washed and dried poly(ethylene terephthalate) (PET) flakes orig...

Europe - EFSA - European Food Safety Authority Publications

13-6-2018

World Variety Produce, Inc. Voluntarily Recalls Spicy Edamame Because Of Undeclared Allergens

World Variety Produce, Inc. Voluntarily Recalls Spicy Edamame Because Of Undeclared Allergens

World Variety Produce, Inc. of Los Angeles, CA is voluntarily recalling Spicy Edamame 7oz, because it contains the undeclared shellfish/crustacean allergen “Oyster Extract” ingredient within the spicy sauce packet. People who have an allergy or severe sensitivity to shellfish run the risk of serious or life-threatening allergic reaction if they consume these products.

FDA - U.S. Food and Drug Administration

29-5-2018

Federal Register Notices

Federal Register Notices

Federal Register notices issued by the Center for Veterinary Medicine.

FDA - U.S. Food and Drug Administration

17-4-2018

Epic Products, LLC, Issues Voluntary Nationwide Recall of All Lots of Euphoric Capsules Due to Presence of Undeclared Sildenafil and Tadalafil

Epic Products, LLC, Issues Voluntary Nationwide Recall of All Lots of Euphoric Capsules Due to Presence of Undeclared Sildenafil and Tadalafil

Overland Park, KS, Epic Products, LLC is voluntarily recalling all lots of Euphoric capsules, packaged in 1 count blister cards, 3 count bottles, and 12 count bottles to the consumer level. FDA analysis found samples of Euphoric to be tainted with undeclared sildenafil and tadalafil, active ingredients in two FDA-approved prescription drug products, also known as phosphodiesterase 5-inhibitors (PDE-5 inhibitors), used to treat male erectile dysfunction (ED). The presence of sildenafil and tadalafil in E...

FDA - U.S. Food and Drug Administration

6-5-2014

Guidance material to doctors and users of contraceptive pills

Guidance material to doctors and users of contraceptive pills

The EU Pharmacovigilance Risk Assessment Committee (PRAC) recently completed a review of the risk of blood clots (VTE) with contraceptive pills and other combined hormonal contraceptives. Combined hormonal contraceptives contain two types of hormone, oestrogen and progesterone, and are available as pills, transdermal patches and vaginal rings.

Danish Medicines Agency

14-2-2019


Opinion/decision on a Paediatric investigation plan (PIP): SER-109 (Eubacterial Spores, Purified Suspension, Encapsulated), decision type: , therapeutic area: , PIP number: P/0390/2018

Opinion/decision on a Paediatric investigation plan (PIP): SER-109 (Eubacterial Spores, Purified Suspension, Encapsulated), decision type: , therapeutic area: , PIP number: P/0390/2018

Opinion/decision on a Paediatric investigation plan (PIP): SER-109 (Eubacterial Spores, Purified Suspension, Encapsulated), decision type: , therapeutic area: , PIP number: P/0390/2018

Europe - EMA - European Medicines Agency

13-2-2019

Consultation: Regulation of software, including Software as a Medical Device (SaMD)

Consultation: Regulation of software, including Software as a Medical Device (SaMD)

The TGA is seeking feedback on how software, including Software as a Medical Device, is regulated in Australia. Closing date: 31 March 2019

Therapeutic Goods Administration - Australia

12-2-2019

Consultation: Proposed regulatory scheme for personalised medical devices, including 3D-printed devices

Consultation: Proposed regulatory scheme for personalised medical devices, including 3D-printed devices

The TGA is seeking feedback on how personalised medical devices are regulated in Australia. Closing date: 31 March 2019

Therapeutic Goods Administration - Australia

12-2-2019

Helicobacter Test INFAI (INFAI GmbH)

Helicobacter Test INFAI (INFAI GmbH)

Helicobacter Test INFAI (Active substance: 13C - urea) - Centralised - Yearly update - Commission Decision (2019)1109 of Tue, 12 Feb 2019

Europe -DG Health and Food Safety

12-12-2018

Therapeutic Goods (Microbiological Standards for Medicines) (TGO 100) Order 2018

Therapeutic Goods (Microbiological Standards for Medicines) (TGO 100) Order 2018

TGO 100 has been registered on the Federal Register of Legislation. It commences on 8 December 2018, repealing and replacing TGO 98

Therapeutic Goods Administration - Australia

17-10-2018

Interact with experts from CDER, CBER & CDRH to learn what’s important when conducting clinical trials & preparing submissions for FDA review.

Register for FDA #CDERSBIA Clinical Investigator Training Course – November 13-15 in Silver Spring, MD.  https:

Interact with experts from CDER, CBER & CDRH to learn what’s important when conducting clinical trials & preparing submissions for FDA review. Register for FDA #CDERSBIA Clinical Investigator Training Course – November 13-15 in Silver Spring, MD. https:

Interact with experts from CDER, CBER & CDRH to learn what’s important when conducting clinical trials & preparing submissions for FDA review. Register for FDA #CDERSBIA Clinical Investigator Training Course – November 13-15 in Silver Spring, MD. https://go.usa.gov/xPqku  pic.twitter.com/EYNZANlgr9

FDA - U.S. Food and Drug Administration

11-10-2018

October is #SIDSAwarenessMonth.  Smoking during pregnancy can lead to complications, premature delivery, low birth weight, stillbirth, and SIDS. Make sure your baby is #safetosleep at  https://women.smokefree.gov/  via @FDATobaccopic.twitter.com/i37QX61Bb

October is #SIDSAwarenessMonth. Smoking during pregnancy can lead to complications, premature delivery, low birth weight, stillbirth, and SIDS. Make sure your baby is #safetosleep at https://women.smokefree.gov/  via @FDATobaccopic.twitter.com/i37QX61Bb

October is #SIDSAwarenessMonth. Smoking during pregnancy can lead to complications, premature delivery, low birth weight, stillbirth, and SIDS. Make sure your baby is #safetosleep at https://women.smokefree.gov/  via @FDATobacco pic.twitter.com/i37QX61Bb7

FDA - U.S. Food and Drug Administration

25-9-2018

Conducting clinical trials & preparing a submission for #FDA review?

Register for #CDERSBIA’s Clinical Investigator Training Course: November 13-15 to learn about FDA regulations, scientific principles for conducting clinical trials, & more!  https://go.

Conducting clinical trials & preparing a submission for #FDA review? Register for #CDERSBIA’s Clinical Investigator Training Course: November 13-15 to learn about FDA regulations, scientific principles for conducting clinical trials, & more! https://go.

Conducting clinical trials & preparing a submission for #FDA review? Register for #CDERSBIA’s Clinical Investigator Training Course: November 13-15 to learn about FDA regulations, scientific principles for conducting clinical trials, & more! https://go.usa.gov/xPqku . pic.twitter.com/Ktqq9Slx0y

FDA - U.S. Food and Drug Administration

24-9-2018

aimed at determining how best to assess safety and effectiveness of digital health technologies without inhibiting patient access. Click on the link to register:  https://bit.ly/2pxdczF 

aimed at determining how best to assess safety and effectiveness of digital health technologies without inhibiting patient access. Click on the link to register: https://bit.ly/2pxdczF 

aimed at determining how best to assess safety and effectiveness of digital health technologies without inhibiting patient access. Click on the link to register: https://bit.ly/2pxdczF 

FDA - U.S. Food and Drug Administration

17-9-2018

 European Medicines Agency (EMA) Human Scientific Committees' Working Party with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 26-Sep-2018, To: 26-Sep-2018

European Medicines Agency (EMA) Human Scientific Committees' Working Party with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 26-Sep-2018, To: 26-Sep-2018

This Healthcare Professionals' Working Party (HCPWP) plenary meeting will include discussions on advances in clinical practice and the scientific and regulatory challenges. Members will also be invited to present how they are including regulatory sciences in fellowships and young researchers’ training. Feedback will be given from the representatives of the Scientific Committees.

Europe - EMA - European Medicines Agency

17-9-2018

 European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 25-Sep-2018, To: 25-Sep

European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP) and with Healthcare Professionals’ Organisations (HCPWP), European Medicines Agency, London, UK, From: 25-Sep-2018, To: 25-Sep

This joint Patients' and Consumers' Working Party (PCWP) and Healthcare Professionals' Working Party (HCPWP) meeting will include results of the 2017 EMA perception survey. EMA regulatory science to 2025 will be discussed together with updates on Good Pharmacovigilance Practices (GVP). The Topic Group on Digital media and health will feedback to the working parties’ members. Participants will also receive an update on ongoing work on electronic product information and on availability of authorised med...

Europe - EMA - European Medicines Agency

17-9-2018

 European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP), European Medicines Agency, London, UK, From: 25-Sep-2018, To: 25-Sep-2018

European Medicines Agency (EMA) Human Scientific Committees' Working Parties with Patients’ and Consumers’ Organisations (PCWP), European Medicines Agency, London, UK, From: 25-Sep-2018, To: 25-Sep-2018

This Patients' and Consumers' Working Party (PCWP) plenary meeting will include discussions on patient engagement along the regulatory lifecycle and visibility of patient input throughout scientific procedures. Feedback will also be given from the representatives of the Scientific Committees.

Europe - EMA - European Medicines Agency

14-9-2018

Federal Register Notice: #FDA Request for Nominations of Voting Members on a Public Advisory Committee; National Mammography Quality Assurance Advisory Committee. Nominations are due by November 5, 2018. For more information, click here:  https://go.usa.g

Federal Register Notice: #FDA Request for Nominations of Voting Members on a Public Advisory Committee; National Mammography Quality Assurance Advisory Committee. Nominations are due by November 5, 2018. For more information, click here: https://go.usa.g

Federal Register Notice: #FDA Request for Nominations of Voting Members on a Public Advisory Committee; National Mammography Quality Assurance Advisory Committee. Nominations are due by November 5, 2018. For more information, click here: https://go.usa.gov/xPgW5  #MedicalDevice

FDA - U.S. Food and Drug Administration

14-9-2018

Federal Register Notice: Request for Nominations on Public Advisory Panels of the Medical Devices Advisory Committee. Nominations are due by October 9, 2018. For more information, click here:  https://go.usa.gov/xPgWa  #MedicalDevice

Federal Register Notice: Request for Nominations on Public Advisory Panels of the Medical Devices Advisory Committee. Nominations are due by October 9, 2018. For more information, click here: https://go.usa.gov/xPgWa  #MedicalDevice

Federal Register Notice: Request for Nominations on Public Advisory Panels of the Medical Devices Advisory Committee. Nominations are due by October 9, 2018. For more information, click here: https://go.usa.gov/xPgWa  #MedicalDevice

FDA - U.S. Food and Drug Administration

14-9-2018

Federal Register Notice: #FDA Request for Nominations for Voting Members on a Public Advisory Committee; Technical Electronic Product Radiation Safety Standards Committee. Nominations are due by November 5, 2018. For more information, click here: https://

Federal Register Notice: #FDA Request for Nominations for Voting Members on a Public Advisory Committee; Technical Electronic Product Radiation Safety Standards Committee. Nominations are due by November 5, 2018. For more information, click here: https://

Federal Register Notice: #FDA Request for Nominations for Voting Members on a Public Advisory Committee; Technical Electronic Product Radiation Safety Standards Committee. Nominations are due by November 5, 2018. For more information, click here: https://go.usa.gov/xPgDd 

FDA - U.S. Food and Drug Administration

5-9-2018

Click the link for more information about the workshop and how to register:  https://go.usa.gov/xPcVM  #MedicalDevice

Click the link for more information about the workshop and how to register: https://go.usa.gov/xPcVM  #MedicalDevice

Click the link for more information about the workshop and how to register: https://go.usa.gov/xPcVM  #MedicalDevice

FDA - U.S. Food and Drug Administration

15-8-2018

Searching the Australian Register of Therapeutic Goods (ARTG)

Searching the Australian Register of Therapeutic Goods (ARTG)

Issue with the Australian Register of Therapeutic Goods (ARTG) search functionality

Therapeutic Goods Administration - Australia

14-8-2018

We are excited by all the feedback we received over the last two days during the Pediatric Medical Device Development meeting. All presentation materials will be available on the Pediatric Medical Device webpage at  https://go.usa.gov/xUF39   #Devices4Kid

We are excited by all the feedback we received over the last two days during the Pediatric Medical Device Development meeting. All presentation materials will be available on the Pediatric Medical Device webpage at https://go.usa.gov/xUF39  #Devices4Kid

We are excited by all the feedback we received over the last two days during the Pediatric Medical Device Development meeting. All presentation materials will be available on the Pediatric Medical Device webpage at https://go.usa.gov/xUF39  #Devices4Kids #MedicalDevice pic.twitter.com/XGwlpgopGn

FDA - U.S. Food and Drug Administration

7-8-2018

EU/3/18/2049 (Inozyme Pharma Ireland Ltd)

EU/3/18/2049 (Inozyme Pharma Ireland Ltd)

EU/3/18/2049 (Active substance: Recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1) - Orphan designation - Commission Decision (2018)5281 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/053/18

Europe -DG Health and Food Safety

6-8-2018

Today is the last day to register to attend the Pediatric Medical Device Development public meeting in person. Click the link to learn more and register. #Pediatrics #medicaldevice  https://go.usa.gov/xUvBD pic.twitter.com/mWuQWK9MLk

Today is the last day to register to attend the Pediatric Medical Device Development public meeting in person. Click the link to learn more and register. #Pediatrics #medicaldevice https://go.usa.gov/xUvBD pic.twitter.com/mWuQWK9MLk

Today is the last day to register to attend the Pediatric Medical Device Development public meeting in person. Click the link to learn more and register. #Pediatrics #medicaldevice https://go.usa.gov/xUvBD  pic.twitter.com/mWuQWK9MLk

FDA - U.S. Food and Drug Administration

1-8-2018

Students are showcasing their work at #FDA’s Annual Summer Student Scientific Poster Daypic.twitter.com/Oq6r1ywLuw

Students are showcasing their work at #FDA’s Annual Summer Student Scientific Poster Daypic.twitter.com/Oq6r1ywLuw

Students are showcasing their work at #FDA’s Annual Summer Student Scientific Poster Day pic.twitter.com/Oq6r1ywLuw

FDA - U.S. Food and Drug Administration

1-8-2018

Today the #FDA is hosting the 2018 Annual Summer Student Scientific Poster Day. We support the next generation of regulatory scientists.pic.twitter.com/mVClAeXKFi

Today the #FDA is hosting the 2018 Annual Summer Student Scientific Poster Day. We support the next generation of regulatory scientists.pic.twitter.com/mVClAeXKFi

Today the #FDA is hosting the 2018 Annual Summer Student Scientific Poster Day. We support the next generation of regulatory scientists. pic.twitter.com/mVClAeXKFi

FDA - U.S. Food and Drug Administration

31-7-2018

During the Pediatric Medical Device Development, public meeting, the #FDA will highlight pathways to encourage the development of medical devices for children. There is still time to register! Click the link to learn more.  https://go.usa.gov/xUvBD  #Pedi

During the Pediatric Medical Device Development, public meeting, the #FDA will highlight pathways to encourage the development of medical devices for children. There is still time to register! Click the link to learn more. https://go.usa.gov/xUvBD  #Pedi

During the Pediatric Medical Device Development, public meeting, the #FDA will highlight pathways to encourage the development of medical devices for children. There is still time to register! Click the link to learn more. https://go.usa.gov/xUvBD  #Pediatrics #medicaldevice pic.twitter.com/UzKDyAyER5

FDA - U.S. Food and Drug Administration

27-7-2018

Withdrawn application:  Raligize, axalimogene filolisbac, Initial authorisation

Withdrawn application: Raligize, axalimogene filolisbac, Initial authorisation

Europe - EMA - European Medicines Agency

17-7-2018

The #FDA invites you to join us and discuss how we can increase medical device options for children at the Pediatric Medical Device Development public meeting. Click the link to register.  #Pediatrics  https://go.usa.gov/xUXHq  #MedicalDevicepic.twitter.c

The #FDA invites you to join us and discuss how we can increase medical device options for children at the Pediatric Medical Device Development public meeting. Click the link to register. #Pediatrics https://go.usa.gov/xUXHq  #MedicalDevicepic.twitter.c

The #FDA invites you to join us and discuss how we can increase medical device options for children at the Pediatric Medical Device Development public meeting. Click the link to register. #Pediatrics https://go.usa.gov/xUXHq  #MedicalDevice pic.twitter.com/hL7vawmOgR

FDA - U.S. Food and Drug Administration

18-6-2018

Updates to the Permissible Ingredients Determination for listed medicines

Updates to the Permissible Ingredients Determination for listed medicines

The Therapeutic Goods (Permissible Ingredients) Determination No. 2 of 2018 has been published on the Federal Register of Legislation

Therapeutic Goods Administration - Australia

7-6-2018

#FDA announces draft Guidance: “Requests for Feedback and Meetings for #MedicalDevice Submissions: The Q-Submission Program”. Comment period closes in 60 days https://go.usa.gov/xQsCe 

#FDA announces draft Guidance: “Requests for Feedback and Meetings for #MedicalDevice Submissions: The Q-Submission Program”. Comment period closes in 60 days https://go.usa.gov/xQsCe 

#FDA announces draft Guidance: “Requests for Feedback and Meetings for #MedicalDevice Submissions: The Q-Submission Program”. Comment period closes in 60 days https://go.usa.gov/xQsCe 

FDA - U.S. Food and Drug Administration

29-5-2018

FDA Open Docket now available for feedback on benefits and risks of software that are not devices-  https://go.usa.gov/xQdfx  #MedicalDevice #21CenturyAct #DigitalHealth

FDA Open Docket now available for feedback on benefits and risks of software that are not devices- https://go.usa.gov/xQdfx  #MedicalDevice #21CenturyAct #DigitalHealth

FDA Open Docket now available for feedback on benefits and risks of software that are not devices- https://go.usa.gov/xQdfx  #MedicalDevice #21CenturyAct #DigitalHealth

FDA - U.S. Food and Drug Administration

29-5-2018

EU/3/18/2026 (Alnylam UK Limited)

EU/3/18/2026 (Alnylam UK Limited)

EU/3/18/2026 (Active substance: Synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2'-fluoro and thirty-five 2'-O-methyl nucleoside residues in the sequence, which is covalently linked via a phosphodiester group to a ligand containing three N-acetylgalactosamine residues) - Orphan designation - Commission Decision (2018)3394 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/019/18

Europe -DG Health and Food Safety